Quantcast

Latest PTC Therapeutics Stories

2011-06-29 07:00:00

ALDERLEY PARK, England and SOUTH PLAINFIELD, N.J., June 29, 2011 /PRNewswire/ -- AstraZeneca and PTC Therapeutics, Inc. (PTC) today announced that they have entered into an exclusive research collaboration and license agreement for the application of PTC's proprietary GEMS(TM) technology (Gene Expression Modulation by Small-molecules) for the discovery and development of potential new therapies for cancer and other diseases for which there is a great unmet medical need. Cancer kills more...

2011-03-30 07:00:00

SOUTH PLAINFIELD, N.J., March 30, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Robert J. Spiegel M.D., FACP as Chief Medical Officer. Dr. Spiegel served previously as Chief Medical Officer of Schering-Plough. PTC also announced today the promotion of Jay Barth, M.D. to Vice President of Clinical Development. (Logo: https://photos.prnewswire.com/prnh/20010919/PTCLOGO ) Dr. Spiegel will report to Stuart W. Peltz, Ph.D., President and CEO of PTC...

2011-03-02 07:00:00

SOUTH PLAINFIELD, N.J., March 2, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that it has identified a chemical series of molecules that penetrates the blood-brain barrier in animal models and reduces levels of BMI1, a protein linked to drug-resistant cancers. The research marks a milestone in PTC's collaboration with the Wellcome Trust and triggers drawdown of a $2.2 million tranche of their $5.4 million Seeding Drug Discovery award. (Logo:...

2011-01-19 07:00:00

SOUTH PLAINFIELD, N.J., Jan. 19, 2011 /PRNewswire/ -- Stuart W. Peltz, Ph.D., President and CEO of PTC Therapeutics, Inc. (PTC), has been elected a Fellow of the American Association for the Advancement of Science (AAAS), the world's largest general scientific society and publisher of the journal Science. AAAS Fellows are chosen by their peers and recognized for their scientifically or socially distinguished efforts to advance science or its applications. (Logo:...

2010-06-07 07:00:00

SOUTH PLAINFIELD, N.J., June 7 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the receipt of a $5.4 million Seeding Drug Discovery (SDD) Award from The Wellcome Trust to support the development of drugs that target Bmi-1, a protein that has been linked to drug resistant cancers. Bmi-1 has been implicated in a wide variety of cancers and has been demonstrated to contribute to drug resistance and treatment failure. It acts by switching off regulatory pathways inside the cell...

2009-12-22 07:00:00

SOUTH PLAINFIELD, N.J., Dec. 22 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the completion of a $50 million financing. The round was led by The Column Group - a new investor - and existing investor Delphi Ventures. The co-lead investors were joined by current investors Credit Suisse First Boston, HBM BioVentures, Novo A/S, Celgene, and other existing and new investors. In conjunction with the Delphi investment, general partner Deepa Pakianathan, Ph.D. will join PTC's...

2009-09-02 07:00:00

SOUTH PLAINFIELD, N.J., Sept. 2 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced an exclusive research collaboration and licensing agreement with Roche for the development of orally bioavailable small molecules utilizing PTC's technology called Gene Expression Modulation by Small-molecules (GEMS(TM)). The collaboration focuses initially on four CNS disease targets to be jointly selected. (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ) Under the terms of the...

2009-09-02 07:00:00

SOUTH PLAINFIELD, N.J., Sept. 2 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that Celgene Corporation has exercised its option to collaborate on advancing drug discovery efforts on an oncology target addressed through the application of PTC's GEMS(TM) (Gene Expression Modulation by Small-molecules) technology. (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ) In September 2007, Celgene made a $20 million equity investment in PTC, which included an option for...

2009-08-10 07:00:00

SOUTH PLAINFIELD, N.J., Aug. 10 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that it has reached a major research milestone in its collaboration with Schering-Plough Corporation (NYSE: SGP) receiving a $2 million payment in connection with the designation of a development candidate for the treatment of hepatitis C virus (HCV) infection. (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ) The collaboration began in March of 2006 based on PTC's HCV efforts that...

2009-06-15 07:00:00

- Funding supports continued focus on rare disorders - SOUTH PLAINFIELD, N.J., June 15 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the receipt of two government grants to support clinical development programs in rare disorders. The U.S. Department of Defense Neurofibromatosis Research Program has awarded an $822,345 grant to support a new open-label Phase 2 clinical trial of PTC's product candidate PTC299 in neurofibromatosis type 2 (NF2), a rare genetic tumor. Separately,...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related